Filing Flows › Guardant Health (GH) › Q4 2025
Guardant Health (GH) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 19, 2026
Guardant Health (GH) reported revenue of $281M for the fourth quarter 2025 (Q4 2025), +39% from a year earlier and +6% from the quarter before. Operating margin was -43.0%, net loss $128M (45.7% of revenue).
Guardant Health, Q4 2025: revenue $281M (+39% year over year), operating margin -43.0%, net loss $128M, operating cash flow −$26.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $281M | +6% | +39% |
| Operating profit | −$121M | — | — |
| Net earnings | −$128M | — | — |
| Operating cash flow | −$26.4M | — | — |
What changed
Revenue was $281.3M in Q4 2025, up 39% year over year and up 6% from the previous quarter. Oncology was the largest line at 68% of revenue.
Operating costs exceeded revenue by $120.8M, an operating margin of -43.0%. Total costs grew 23% against revenue growth of 39%. The fastest-growing cost line was Sales & marketing (+37%). The quarter ended with a net loss of $128.5M, wider than the previous quarter's $92.7M loss.
Operating cash flow was −$26.4M. Non-cash charges added back $10.1M of depreciation and amortization and $43.2M of share-based compensation. Working capital and other items added $48.9M. Capital expenditures of $27.8M exceeded it, leaving free cash flow of −$54.2M.
Questions
What was Guardant Health's revenue in the fourth quarter 2025?
Guardant Health (GH) reported revenue of $281M for the fourth quarter 2025 (Q4 2025), +39% from a year earlier and +6% from the quarter before.
Was Guardant Health profitable in the fourth quarter 2025?
Operating loss was $121M (-43.0% of revenue) and net loss $128M.
Source: Guardant Health 10-K on SEC EDGAR.